Please login to the form below

Not currently logged in
Email:
Password:

galcanezumab

This page shows the latest galcanezumab news and features for those working in and with pharma, biotech and healthcare.

Lundbeck bolts on migraine drug via $1.95bn deal to buy Alder

Lundbeck bolts on migraine drug via $1.95bn deal to buy Alder

Alder’s drug is given every three months, whereas Amgen’s  Aimovig(erenumab) and Lilly’s  Emgality(galcanezumab) are taken once a month and Teva’s  Ajovy(fremanezumab) is dosed either

Latest news

More from news
Approximately 1 fully matching, plus 17 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
An agency called Owen

We’re a Healthcare Communications Agency specialising in Multi-channel Marketing to make you Digitally Fitter, Stronger & Faster....

Latest intelligence

The 2019 WHO essential medicine list: Narrowing the access gap to innovative cancer treatments
The essential medicine list (EML) contains treatments considered to be the most effective and safe in targeting global health concerns. On 9 July 2019, the World Health Organization (WHO) published...
NICE
Evolution or revolution: the latest review of NICE methods
By Leela Barham...
PRO
Integrating patient reported outcomes into clinical trials
How capturing the patient voice is unlocking medicines’ commercial potential...

Infographics